IPATential150: abiraterone−ipatasertib combination effective in treating aggressive prostate cancer

Written by Louis Gautier, Future Science Group

cancer cell, cancer, oncology

A recent Phase III clinical trial, led by the Institute of Cancer Research (ICR) and Royal Marsden NHS Foundation Trust (both London, UK), has demonstrated that dual inhibition of androgen receptor and AKT signaling with abiraterone and ipatasertib, respectively, extends progression-free survival in men with aggressive prostate cancers lacking PTEN. The latest results from the IPATential150 study, published recently in The Lancet, provide the first strong evidence of the benefit of combining the two drugs in particularly aggressive prostate cancers. The trial found that giving ipatasertib plus abiraterone (Zytiga®) as a first-line treatment reduced the risk of death or cancer...

To view this content, please register now for access

It's completely free